RECOMBINANT ANTIBODIES IN ANTI-VIRAL THERAPY: ACHIEVEMENTS AND PERSPECTIVES
| Autor: | A S Oksanich, A A Nikonova, Zverev Vv |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug medicine.drug_class viral infections media_common.quotation_subject 030106 microbiology recombinant antibodies Medicine (miscellaneous) Monoclonal antibody Microbiology law.invention 03 medical and health sciences Recombinant antibodies law Medicine Viral therapy media_common therapy biology business.industry Cancer General Medicine medicine.disease Virology QR1-502 Transplantation Recombinant DNA biology.protein Antibody business immunoglobulin |
| Zdroj: | Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 0, Iss 6, Pp 114-123 (2018) |
| ISSN: | 2686-7613 0372-9311 |
| Popis: | More than 60 recombinant monoclonal antibodies (mAbs) have been developed for the treatment of various diseases in the last 20 years. About 30 antibody preparations are approved for use in therapy, including large group of drugs against cancer. In addition, mAbs are used in transplantation, for the treatment of cardiovascular, autoimmune and, in rare cases, infectious diseases. Despite the fact that tens millions of people die every year from viral diseases, only one drug based on recombinant antibodies for the prevention of RSV in children is currently allowed. This review focuses on approaches to generate therapeutic mAbs to fight viral infection, examples of mAb therapies for viral infections, and the challenges of developing such therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|